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Phosphodiesterase type 5 inhibition may
reduce diastolic function in women with
ischemia but no obstructive coronary artery
disease
Michael D. Nelson1,2,3, Puja K. Mehta1, Janet Wei1, Behzad Sharif2, Louise E. J. Thomson4, Daniel Berman4,
Debiao Li2 and C. Noel Bairey Merz1*
Abstract
Background: Ischemia, in the absence of obstructive coronary artery disease, is prevalent in women, and
associated with increased risk for major cardiovascular events. Coronary microvascular dysfunction is prevalent
in these patients, and associated with impaired diastolic function. Despite our general understanding, however,
optimal treatment of this cohort remains elusive.
Methods: To address this knowledge gap, we performed an open-label treatment trial to assess whether
phosphodiesterase type 5 inhibition improves coronary microvascular perfusion and diastolic function in women
with signs and symptoms of ischemia but no evidence of obstructive coronary artery disease. Left ventricular
morphology and function, along with myocardial perfusion reserve index, were assessed by contrast-enhanced
cardiac magnetic resonance imaging.
Results: A total of five women enrolled of which four completed the trial, while one was withdrawn by the
investigators after developing dyspnea 1 week after treatment. Her symptoms resolved after cessation of the study
medication. In contrast to our hypothesis, phosphodiesterase type 5 inhibition reduced the rate of circumferential
strain in diastole in all four women who completed the trial (that is, diastolic dysfunction). This impairment could
not be explained by changes in heart rate, contractility, blood pressure, or preload, and was not associated with a
change in myocardial perfusion reserve index. Frequency of angina also tended to increase with treatment, with
the greatest increase occurring in the patient with the greatest impairment in diastolic strain.
Conclusions: Taken together, these data question the efficacy of phosphodiesterase type 5 inhibition to treat
women with ischemic heart disease, and highlight the need for further investigation.
Keywords: Women’s ischemic syndrome, Coronary microvascular dysfunction, Diastolic dysfunction, Myocardial
perfusion reserve index, Phosphodiesterase type 5 inhibition
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Background
Ischemia, in the absence of obstructive coronary artery
disease (CAD), is prevalent in women, and associated with
increased risk for major cardiovascular events, including
myocardial infarction, stroke, heart failure, and sudden
cardiac death [1]. Sex-specific research initiatives, including
the Women’s Ischemia Syndrome Evaluation (WISE) study
sponsored by the National Heart, Lung, and Blood Insti-
tute (NHLBI), have established coronary microvascular
dysfunction (CMD) and diastolic dysfunction as important
etiologic features of this disease [2, 3]. Despite these
advancements, effective treatment remains elusive [4].
Phosphodiesterase (PDE) 5 is expressed in vascular
smooth muscle cells and regulates vasorelaxation by
catabolizing cyclic guanosine monophosphate (cGMP),
the downstream target of nitric oxide. PDE5 is upregu-
lated in stress states [5], and thus could contribute to
the pathophysiology of ischemic heart disease in women.
Accordingly, we sought to determine whether PDE5 in-
hibition improves CMD-related perfusion and diastolic
function in women with signs and symptoms of ischemia
but no obstructive CAD.
Methods
Patients were recruited from the WISE-Coronary Vascular
Dysfunction study (NCT00832702), which is a NHLBI-
sponsored investigation designed to improve diagnostic
testing and advance new hypotheses relative to the patho-
physiology of ischemic heart disease in women. Women
undergoing clinically ordered coronary angiography for
suspected ischemia, but without obstructive CAD [6],
were recruited. Exclusion criteria included: age <18 years,
body mass index (BMI) ≥44 kg/m2, irregular heartbeat,
renal failure, concurrent use of nitrates, alpha-adrenergic
receptor blockers, or PDE inhibitors, as well as any
contraindication to magnetic resonance imaging (MRI).
Table 1 Patient characteristics, medical history, treatment history, and medication usage
Patient #
1 2 3 4 5
Age, years 55 67 56 65 82
Body mass index, kg/m2 23 26 21 29 19
Heart rate, bpm 53 63 80 48 41
Systolic blood pressure, mmHg 126 96 153 112 100
Diastolic blood pressure, mmHg 53 53 81 59 53
LV end-diastolic pressure, mmHg 15 17 — 20 —
Medical history
Hypertension — Y Y Y Y
Dyslipidemia Y Y — Y —
Diabetes mellitus — — — Y —
Tobacco smoking — — — — —
Myocardial infarction — — — Y —
PDE5-inhibitor
Drug Tadalafil Tadalafil Tadalafil Sildenafil Sildenafil
Dose 5 mg 20 mg 5 mg 20 mg TID 10 mg TID
Frequency Every 3 days Every 3 days Every 3 days Daily Daily
Concomitant medications
Antiplatelet Aspirin Aspirin Aspirin Aspirin Aspirin
Beta-blocker Carvedilol Atenolol — Carvedilol Atenolol
Calcium channel blocker — — Diltiazem — —
Statin Pitavastatin Rosuvastatin — Atorvastatin —
Diuretic — HCTZ — — HCTZ Furosemide
ACE-I/ARB — Ramipril Losartan Lisinopril Losartan
Other Levothyroxine Amitriptyline — Metformin Levothyroxine
Other Prometrium (progesterone) — — — Dronedarone
Other Estradiol — — — —
ACE-I/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, bpm beats per minute, HCTZ hydrochlorothiazide, LV left ventricular, PDE5
phosphodiesterase 5, TID three times a day, Y, Yes. Patient 5 was withdrawn by the investigators after developing dyspnea 1 week after treatment
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Patients were treated for 2 weeks in an open-label,
non-randomized protocol with the PDE5 inhibitor
tadalafil or sildenafil, as per the ordering physician’s
instructions (Table 1). In all cases, the final capsule was
ingested the night before the follow-up MRI.
Cardiac MRI was performed at baseline and after
2 weeks of treatment (Siemens 3 T Verio; Erlangen,
Germany). Imaging included cines for morphological and
functional analysis (four chamber), mid-ventricular short-
axis tissue tagging for strain analysis (HARP, Diagnosoft;
Durham, NC, USA) [2], and first-pass perfusion imaging
(base, mid, and apex; 0.05 mmol/kg gadolinium) at rest
and in response to 140 mcg/kg per minute adenosine
stress for calculation of myocardial perfusion reserve
index (MPRI) [6]. Image analysis for MPRI was performed
manually using a DICOM viewer (OsiriX by Pixmeo,
Bernex, Switzerland).
Angina was assessed before and after treatment using
the Seattle Angina Questionnaire [7].
Individual data are presented wherever possible. Data
comparing the treatment effect are presented as mean ±
standard error. Linear regression was used to determine
the relationship between diastolic function and angina
frequency. Due to the small sample size, statistical
analysis was not performed.
Results
Patient characteristics are reported in Table 1. A total of
five women enrolled, four completed the trial, while one
was withdrawn by the investigators after developing
dyspnea 1 week after treatment. Her symptoms resolved
after cessation of the study medication.
The major novel finding of this investigation was that
PDE5 inhibition reduced the rate of circumferential
strain in diastole in all four women who completed the
trial (that is, diastolic dysfunction; Fig. 1). This impair-
ment could not be explained by: changes in heart rate,
that is, 58 ± 6 beats per minute (bpm) versus 61 ±
6 bpm; contractility, that is, left ventricular (LV) ejection
fraction 70 ± 1% versus 67 ± 1% and peak circumferential
strain −20.7 ± 1.0% versus −20.2 ± 1.4%; or preload, that
is, LV end-diastolic volume 108 ± 8 ml versus 109 ± 3 ml
and left atrial volume 56 ± 10 ml versus 61 ± 11 ml; and
was not associated with a change in MPRI 2.32 ± 0.10
versus 2.39 ± 0.06 (pre versus post).
The frequency of angina also tended to increase
with treatment, with the greatest increase occurring
in the patient with the greatest impairment in dia-
stolic strain (Fig. 1).
Discussion
In contrast to our hypothesis, PDE5 inhibition appears
to worsen left ventricular relaxation in women with
angina but no evidence of obstructive CAD. That one
patient developed dyspnea while on the drug is consist-
ent with the diastolic changes observed in the other four
patients, and raises concern about the safety of PDE5
inhibition in this population. Our results add to a grow-
ing body of literature questioning the safety [8] and
efficacy [9] of PDE5 inhibition to treat heart disease,
currently an off-label indication (other than pulmonary
hypertension).
The mechanism responsible for the reduction in dia-
stolic function remains unknown. We did not observe
frank hemodynamic changes, arguing against extrinsic
factors. It is therefore interesting to speculate that
adverse cellular signaling may have played a role,
especially since the two patients with the greatest
impairment/symptoms (P4 and P5) were treated with
sildenafil, which is far less selective for PDE5 and also
Fig. 1 Phosphodiesterase 5 inhibition worsens diastolic function and symptoms of angina in women with ischemic syndrome. Left: Magnetic
resonance tissue tagging was performed on two consecutive mid-short axis slices before and after treatment, and analyzed using commercially
available software to assess the rate of circumferential strain in diastole. Individual data are shown, illustrating a reduction in all four patients who
completed the trial. Group data (mean and standard error) are also reported (black markers). Right: Relationship between changes in self-reported
angina frequency (Seattle Angina Questionnaire) and the change in diastolic circumferential strain rate. PDE5 phosphodiesterase 5
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inhibits PDE1, which hydrolyzes cyclic adenosine mono-
phosphate (cAMP) as well as cGMP.
This study is not without limitation however. For ex-
ample, the small sample size and lack of a control group
limits the broad application and statistical verification of
these results. Moreover, participants were not random-
ized, nor were they blinded to the treatment. Despite
these limitations, however, the uniform nature of our
results warrants serious consideration and future investi-
gation. In particular, a randomized placebo-controlled
trial in a larger study sample is needed to fully elucidate
the therapeutic efficacy of PDE5 inhibitors in CMD.
Conclusion
Taken together, these data question the efficacy of
phosphodiesterase type 5 inhibition to treat women with
ischemic heart disease, and highlight the need for further
investigation.
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